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INTRODUCTION 
Breast cancer is the most common cause of cancer death in 
women [1]. Systemic treatments for breast cancer include cy-
totoxic, hormonal, and immunotherapeutic agents. Although 
many anti-cancer therapies are clinically applicable, they gen-
erally have strong cellular cytotoxicity and severe side effects 
[2]. To develop novel strategies that increase the therapeutic 
efficacy and minimize the systemic toxicity of chemothera-
peutic agents, more efforts are being directed towards investi-
gating dietary supplements and other phytotherapeutic agents 
for their synergistic efficacy with anticancer drugs. Silibinin is 
one of these agents that has shown chemopreventive and anti-
cancer effects in various studies [3-6]. 
Silibinin is the major active constituent of silymarin, which 
is a mixture of flavonolignans extracted from blessed milk this-
tle (Silybum marianum). Milk thistle extracts have been used 
for centuries in traditional medicine, and they are widely con-
sumed herbal remedies with several putative beneficial effects 
on health, such as hepatoprotective properties. Consuming 
silibinin is safe and non-toxic in animals and humans, as no 
substantial adverse effects have been reported when silibinin 
is given to humans and rodents at doses as high as 1% (w/w) 
or 2 g/kg body weight [7,8]. Many studies have shown that silib-
inin blocks experimentally induced malignancies of the pros-
tate, skin, and colon [8-10]. Human trials of silibinin are under-
way for treating prostate cancer, and a completed phase I study 
has shown no toxic effects [11]. Silibinin plays an important 
role in breast cancer cells [2,12]. However, the molecular mech-
anisms associated with the chemopreventive effects of silibinin 
have not been clearly and systemically elucidated for breast 
cancer. Therefore, we initiated studies to determine whether 
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Purpose: Chemotherapies for breast cancer generally have strong 
cellular cytotoxicity and severe side effects. Thus, significant 
emphasis has been placed on combinations of naturally occur-
ring chemopreventive agents. Silibinin is a major bioactive flavo-
nolignan extracted from milk thistle with chemopreventive activi-
ty in various organs including the skin, prostate, and breast. How-
ever, the mechanism underlying the inhibitory action of silibinin in 
breast cancer has not been completely elucidated. Therefore, we 
investigated the effect of silibinin in MCF-7 human breast cancer 
cells and determined whether silibinin enhances ultraviolet (UV) 
B-induced apoptosis. Methods: The effects of silibinin on MCF-7 
cell viability were determined using the MTT assay. The effect of 
silibinin on PARP cleavage, as the hallmark of apoptotic cell death, 
and p53 protein expression in MCF-7 cells was analyzed using 
Western blot. The effect of silibinin on UVB-induced apoptosis in 
MCF-7 cells was analyzed by flow cytometry. Results: A dose- and 
time-dependent reduction in viability was observed in MCF-7 cells 
treated with silibinin. Silibinin strongly induced apoptotic cell death 
in MCF-7 cells, and induction of apoptosis was associated with 
increased p53 expression. Moreover, silibinin enhanced UVB-   
induced apoptosis in MCF-7 cells. Conclusion: Silibinin induced 
a loss of cell viability and apoptotic cell death in MCF-7 cells. 
Furthermore, the combination of silibinin and UVB resulted in an 
additive effect on apoptosis in MCF-7 cells. These results sug-
gest that silibinin might be an important supplemental agent for 
treating patients with breast cancer. 
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silibinin induces apoptosis in breast cancer cells.
Ultraviolet (UV) radiation comprises UVA (320-400 nm) 
and UVB (280-320 nm), the latter being crucial for inducing 
cutaneous malignancy and suppressing the immune system. 
UVB also activates various signal transduction pathways and 
induces the expression of several specific genes [13]. Lower 
doses of UVB cause DNA mutations leading to tumor initia-
tion, whereas high doses result in irreparable DNA damage 
causing apoptosis and eventually cell death [14]. Ecological 
studies have suggested a possible association between to UVB 
radiation and reduction in the risk of breast cancer [15]. In a 
recent study, UV irradiation induced apoptosis in MCF-7 cells 
[16]. Furthermore, Silibinin enhances apoptosis in response 
to UVB-induced moderate/excessive damage in spontaneous-
ly immortalized human keratinocyte HaCaT cells [17], indi-
cating that silibinin may enhance UVB-induced apoptosis in 
breast cancer cells. Thus, we investigated whether the combi-
nation of silibinin and UVB would affect apoptosis in MCF-7 
human breast cancer cells. In this study, we established an ex-
perimental breast cancer model to examine the effect of silib-
inin in MCF-7 cells and explored the possibility of using silib-
inin as a supplemental agent for patients with breast cancer. 
METHODS
Materials 
Antibodies against PTEN and p53 were purchased from San-
ta Cruz Biotechnology (Santa Cruz, USA). Anti-PARP anti-
body was purchased from Cell Signaling Technology (Beverly, 
USA). Fetal bovine serum (FBS) and charcoal-dextran treated 
FBS were obtained from Gibco BRL (Life Technologies, Grand 
Island, USA). Silibinin (2,3-dihydro-3-[4-hydroxy-3-methoxy-
phenyl]-2-[hydroxymethyl]-6-[3,5,7-trihydroxy-4-oxobenzo-
pyran-2-yl]benzodioxin), Hanks balanced salt solution, Dul-
becco’s Modified Eagle’s Medium (DMEM), phenol red-free 
DMEM, and β-actin antibody were obtained from Sigma 
Chemical Co.(St. Louis, USA).
Cell culture 
A human breast cancer cell line (MCF-7) was obtained from 
the American Type Culture Collection (Rockville, USA). The 
cells were cultured in DMEM containing 10% FBS, 2 mM glu-
tamine, antibiotics (penicillin G, 60 mg/L; streptomycin, 100 
mg/L; amphotericin B, 50 μL/L) under a humid atmosphere 
(37°C, 5% CO2, 95% air).
Determination of cell viability
The effect of silibinin on MCF-7 cell viability was determined 
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT; Sigma) assay. Briefly, 2×l0
4 cells/well were treat-
ed with various concentrations of silibinin (0-200 μM). After 
a 24-hour incubation the cells were washed twice with phos-
phate buffered saline (PBS) and MTT (0.5 mg/mL PBS) was 
added to each well and incubated at 37°C for 30 minutes. The 
formazan crystals that formed were dissolved by adding dimeth-
yl sulfoxide (100 μL/well), and the absorbance was read at 570 
nm using a microplate reader (Model 3550; BIO-RAD, Rich-
mond, USA). The reduction in cell viability after silibinin treat-
ment was expressed in terms of control (nonsilibinin treated) 
cells.
Western blot analysis 
After washing the cell pellets with PBS and harvesting, they 
were lysed with lysis buffer. After a 30-minute incubation at 
4°C, cellular debris was removed by centrifugation at 10,000×g 
for 30 minutes, and the supernatants were analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. Electro-
phoretic transfer from the slab gel to nitrocellulose paper and 
subsequent immunoblotting was performed by incubating the 
gels with primary antibodies against PARP, PTEN, p53, and 
β-actin followed by further incubation with HRP-conjugated 
secondary antibody. Reactive proteins were detected using the 
enhanced chemiluminescence system (ECL; Amersham Life 
Sciences, Arlington Heights, USA).
UVB irradiation 
We used a UVB cross-linker (6×8 W, 312 nm, Model CL-
508M; Vilber Lourmat, Paris, France) for UVB irradiation. 
Briefly, serum-starved confluent cells were rinsed twice with 
PBS, and all irradiations were performed under a thin layer of 
PBS. Immediately after irradiation, fresh serum-free medium 
was added to the cells. Mock-irradiated controls followed the 
same schedule of medium changes without UVB irradiation. 
Flow cytometric analysis
To analyze the apoptotic cells, MCF-7 cells were plated in 
60-mm dishes and 24 hours later either, exposed to UVB, treat-
ed with silibinin alone, or treated with silibinin (200 μM) before 
UVB (25 mJ/cm
2) exposure. At the end of the 24-hour incu-
bation, attached MCF-7 cells were harvested by trypsinization 
and pooled with floating cells. The cells were then washed twice 
with ice-cold PBS and stained with FITC-conjugated annexin 
V and propidium iodide according to the manufacturer’s instruc-
tions (Invitrogen, Carlsbad, USA). Stained cells were measured 
at a fluorescence emission wavelengths of 530 nm and 575 nm 
using a 488 nm excitation wavelength. Apoptotic cells were 
analyzed by fluorescence activated cell sorting (FACScalibur; 
BD Biosciences, San Jose, USA).10   Eun-Mi Noh, et al.
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Data analysis 
All experiments were repeated at least three times. The data 
are presented as means±standard errors. The statistical analy-
sis was performed using paired Student’s t-test, and p<0.05 
was considered statistically significant.
RESULTS
Silibinin induced loss of MCF-7 cell viability
MTT assays were performed to determine MCF-7 cell via-
bility after the silibinin incubation (for silibinin structure, Fig-
ure 1). As shown in Figure 2, treating MCF-7 cells with 200 μM 
silibinin for 48 hours resulted in no significant effect on cell vi-
ability. However, cell viability decreased significantly when the 
cells were incubated with silibinin for 72 hours. Moreover, ex-
posure of MCF-7 cells to silibinin resulted in a dose dependent 
loss of cell viability. Cell viability decreased significantly when 
the cells were incubated with 200 μM silibinin for 72 hours.
Silibinin induced apoptotic cell death in MCF-7 cells
PARP cleavage in silibinin-treated and untreated cells were 
measured to investigate the apoptotic mechanism of silibinin 
on MCF-7 cells. MCF-7 cells were cultured with various con-
centrations of silibinin for 72 hours, and PARP cleavage of 
MCF-7 cells was analyzed by Western blot using a specific anti-
PARP antibody. The data showed that 200 μM silibinin strongly 
induced PARP cleavage (Figure 3). 
Silibinin induced p53 expression in MCF-7 cells
We measured p53 expression to determine the possible role 
of p53 in the induction of apoptosis by silibinin in MCF-7 cells. 
The effect of silibinin on p53 protein expression was deter-
mined using Western blot analysis. MCF-7 cells were treated 
with various concentrations of silibinin (0-200 μM) for 72 hours, 
and whole cell extracts were used for the p53 Western blot anal-
ysis. As shown in Figure 4, silibinin increased the p53 level in 
a dose-dependent manner. Interestingly, silibinin had no effect 
on PTEN, known as a tumor suppressor protein, expression 
in MCF-7 cells. 
Silibinin enhanced UVB-induced apoptosis in MCF-7 cells
We investigated whether the combination of silibinin and 
UVB affected apoptosis in MCF-7 cells. MCF-7 cells were 
treated with 200 μM silibinin, UVB alone, or in combination 
for 72 hours to determine the effect of combined silibinin and 
UVB on apoptosis. We pretreated cells with 200 μM silibinin 
Figure 2. Effects of silibinin on MCF-7 cell viability. (A) Cells were cultured in 96-well plates until 90% confluence and 200 μM silibinin was then added 
for 24, 36, 48, and 72 hr. The MTT assay was used to detect cell viability. The optical density (O.D.) value of the control was regarded as 100%. Data 
points are the means±SEs of more than three experiments (p<0.005). (B) Cells were cultured in 96-well plates until 90% confluence and various con-
centrations of silibinin (0-200 μM) were added for 72 hr. The MTT assay was used to detect cell viability. The O.D. value of the control was regarded 
as 100%. Data points are the means±SEs of more than three experiments (p<0.005). 
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Figure 3. Effect of silibinin on PARP cleavage in MCF-7 cells. MCF-7 
cells (5×10
6 cells) were treated with various concentrations of silibinin 
(0-200 μM) for 72 hr, and whole cell extracts were used for Western 
blot analysis of PARP. β-actin was used as the loading control. 
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Figure 1. Structure of silibinin.
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prior to UVB irradiation and MCF-7 cell viability was mea-
sured by the MTT assay. As shown in Figure 5, UVB induced 
a significant loss of MCF-7 cell viability. Cell viability in silib-
inin-pretreated cells was significantly less than with silibinin 
alone. Florescence staining was performed to determine wheth-
er a decrease in MCF-7 cell viability after silibinin treatment 
and UVB irradiation was the result of apoptosis. Apoptosis in 
MCF-7 cells was further quantitatively analyzed by flow cytom-
etry. As shown in Figure 6, UVB resulted in only 4.8% apop-
totic cells compared with the control; however, silibinin pre-
treatment resulted in 8.8% apoptotic cells, accounting for a 
significant enhancement in UVB-induced apoptosis.
DISCUSSION
Chemotherapeutic agents have been developed to counter 
the continuing breast cancer problem. However, most chemo-
therapeutic drugs effectively target rapidly dividing cells caus-
ing damage and are thus referred to as “cytotoxic drugs.” These 
cytotoxic drugs cause a wide variety of side-effects, such as nau-
sea, immunosuppression, myelosuppression, cardiotoxicity, 
hepatotoxicity, nephrotoxicity, and non-specific neurocogni-
tive problems. Cytotoxic drugs could face limited clinical appli-
cation due to their high toxicity and increased chemoresistance, 
so combination therapy/prevention is gaining increased atten-
tion as an effective alternative to increase therapeutic efficacy 
and minimize the systemic toxicity of these chemotherapeutic 
agents.
Interest in naturally occurring products is increasing for the 
prevention of carcinogenesis. Based on this idea, certain foods 
such as vegetables, fruits, and grains, as well as other phytother-
apeutic agents offer high anticancer efficacy and low toxicity to 
normal tissue. One such dietary agent is silibinin, which has a 
wide range of pharmacological effects, such as inhibition of DNA 
synthesis, cell proliferation, cell cycle progression, and apoptosis 
in various cancer cell lines, including breast cancer [3-6]. More-
over, the administration of this compound to various animals 
has been shown to be nontoxic in many studies [18,19]. How-
ever, the molecular mechanisms associated with the anticancer 
effects of silibinin have not been clearly elucidated for breast 
cancer. The inhibition of cell viability by silibinin requires p53 
protein expression, and p53-deficient cells are less susceptible 
to silibinin-induced apoptosis [20]. Therefore, we established 
an experimental breast cancer model to examine the effect of 
silibinin in MCF-7 cells, which express wild-type p53. 
In this study, MTT assays were performed to determine cell 
viability. No effect of low concentrations of silibinin (≤100 μM) 
on cell viability was observed. However, at high silibinin concen-
trations (≥200 μM), cell viability decreased significantly to ap-
proximately 60% of control levels. These findings suggest that 
the effect of silibinin on MCF-7 cells was dose dependent. In 
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Figure 4. Effect of silibinin on p53 and PTEN expression in MCF-7 cells. MCF-7 cells (5×10
6 cells) were treated with various concentrations of silibinin 
(0-200 μM) for 72 hr. Cells were lysed with lysis buffer and the amounts of p53/PTEN and β-actin as a loading control were measured by Western blot 
(A). The relative density of the electrophoretic band was obtained with a LAS-1000 analyzer (Fujifilm, Japan) (B). Data are means±SEs of four sepa-
rate experiments (p<0.005).
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Figure 5. Effect of silibinin and ultraviolet (UV) B on MCF-7 cell viability. 
MCF-7 cells were treated with 200 μM silibinin and UVB alone or in com-
bination for 72 hr. The MTT assay was used to detect cell viability. The 
optical density value of the control was regarded as 100%. Data points 
are the means±SEs of more than three experiments.
*p<0.001 (Student’s t-test).12   Eun-Mi Noh, et al.
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1999, Bhatia et al. [21] reported that treating of prostate, breast, 
and cervical carcinoma cells with silibinin results in a highly sig-
nificant inhibition of cell growth and DNA synthesis in a time-
dependent manner with a large loss of cell viability only in the 
case of cervical carcinoma cells. Tyagi et al. [3] reported that silib-
inin alone results in growth inhibition in a dose-and time-de-
pendent manner. Moreover they suggested that silibinin syn-
ergizes with conventional cytotoxic agents during breast cancer 
treatment. Recently, several studies reported the mechanism 
underlying the cytotoxicity of silibinin in breast cancer [2,12].
Apoptosis is a distinctive form of cell death, resulting in the 
death of specific cell populations during physiological pro-
cesses [22,23]. Inhibiting apoptosis is a possible mechanism of 
tumor development, and many chemopreventive agents act 
through the induction of apoptosis to inhibit the carcinogenic 
process. Therefore, the induction of apoptosis in breast cancer 
cells may be one of the mechanisms of the anticancer effect of 
silibnin. Here, we found that silibinin induced apoptotic cell 
death in MCF-7 cells. PARP cleavage in silibinin-treated and 
untreated cells was measured, as PARP cleavage is the hallmark 
of apoptotic cell death [24]. Silibinin (200 μM) strongly induced 
PARP cleavage. This finding was similar to another study show-
ing that silibinin strongly induces apoptosis in renal cell carci-
noma cells [4].
It has long been recognized that tumor suppressor protein 
p53 is induced by DNA damage [20]. The resulting increase in 
p53 leads either to the induction of cell cycle arrest or apopto-
sis. Thus, functional p53 provides a protective effect against 
tumor growth [25]. Additionally, several studies have shown 
that silibinin induces p53-dependent apoptosis in various can-
cer cells [26,27]. Therefore, we measured p53 expression to de-
termine the possible role of p53 in the induction of apoptosis 
by silibinin in MCF-7 cells. Silibinin increased the level of p53 
in a dose-dependent manner, which may have occurred due 
to increased half-life. However, silibinin has no effect on PTEN 
expression in MCF-7 cells [28], indicating that silibinin induces 
p53 protein expression specifically in breast cancer cells. Fur-
ther studies are in progress to define the role of p53-indepen-
dent pathway in the induction of silibinin-induced apoptosis 
in MCF-7cells.
In 2003, Ferguson et al. [16] reported that apoptosis can be 
induced in MCF-7 cells after UV treatment. Then, Mohan et 
al. [29] reported that UVB showed a dose- and time-dependent 
apoptotic death in human epidermoid carcinoma cells, and 
that silibinin pre-treatment resulted in an increase in UVB-
induced apoptosis. In this study, we found that UVB caused a 
significant increase in loss of viability and apoptosis in MCF-7 
cells. Cell viability was significantly less in silibinin-pretreated 
cells than in silibinin or UVB irradiated alone cells, and apop-
tosis was greater. These results suggest that silibinin enhanced 
UVB-induced apoptosis in MCF-7 cells. These findings encour-
age further mechanistic and in vivo studies to develop silibinin 
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as a chemopreventive or chemotherapeutic agent that enhances 
UVB-induced apoptosis in human breast cancers. 
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